Payment overview · 2025
General Payments
$320.21
10 reported records · 6 companies
Healthcare provider profile · identity verified
Luis M Benavides, MD
Allopathic & Osteopathic Physicians|Family Medicine · LAREDO, TX · NPI 1780656686
Verified facts
What the public records show
CMS Open Payments records show Luis M Benavides, MD received $320.21 in general payments during 2025 across 10 reported records.
ViiV Healthcare Company accounted for 55.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Rexulti.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 383 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rexulti by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ISENTRESS as an associated drug or biological on 37 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Isentress by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Dovato by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $177.00 | 55.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $73.07 | 22.8% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $22.84 | 7.1% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.80 | 6.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.76 | 4.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.74 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $320.21 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $177.00 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $44.00 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $44.00 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $29.07 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $22.84 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $19.80 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $13.76 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.76 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.74 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 383 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 71 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
383 | 55 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
71 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
52 | 13 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | ISENTRESS open payments reported associated product |
CMS Open Payments — General Payments 37 supporting records · 24 recipient NPIs · example record 1238003286 |
Isentress · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 976 | 241 |
| Losartan Potassium | Losartan Potassium | 692 | 179 |
| Levothyroxine Sodium | Levothyroxine Sodium | 656 | 154 |
| Alprazolam | Alprazolam | 574 | 110 |
| Amlodipine Besylate | Amlodipine Besylate | 551 | 149 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 535 | 174 |
| Mirtazapine | Mirtazapine | 482 | 99 |
| Furosemide | Furosemide | 423 | 112 |
| Metformin Hcl | Metformin Hcl | 420 | 107 |
| Metoprolol Succinate | Metoprolol Succinate | 389 | 94 |
| Farxiga | Dapagliflozin Propanediol | 385 | 78 |
| Jardiance | Empagliflozin | 383 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 376 | 90 |
| Eliquis | Apixaban | 343 | 55 |
| Gabapentin | Gabapentin | 289 | 82 |
| Lisinopril | Lisinopril | 282 | 76 |
| Montelukast Sodium | Montelukast Sodium | 275 | 79 |
| Donepezil Hcl | Donepezil Hcl | 273 | 50 |
| Trazodone Hcl | Trazodone Hcl | 268 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 265 | 88 |
| Clopidogrel | Clopidogrel Bisulfate | 247 | 62 |
| Famotidine | Famotidine | 220 | 57 |
| Carvedilol | Carvedilol | 212 | 59 |
| Sertraline Hcl | Sertraline Hcl | 193 | 37 |
| Omeprazole | Omeprazole | 191 | 63 |
| Memantine Hcl | Memantine Hcl | 188 | 28 |
| Tramadol Hcl | Tramadol Hcl | 184 | 64 |
| Nifedipine Er | Nifedipine | 177 | 48 |
| Divalproex Sodium | Divalproex Sodium | 174 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 174 | 35 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 168 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 166 | 62 |
| Metoprolol Tartrate | Metoprolol Tartrate | 158 | 38 |
| Clonazepam | Clonazepam | 153 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 153 | 55 |
| Potassium Chloride | Potassium Chloride | 152 | 47 |
| Hydralazine Hcl | Hydralazine Hcl | 147 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 145 | 35 |
| Cefdinir | Cefdinir | 142 | 108 |
| Finasteride | Finasteride | 141 | 31 |
| Xarelto | Rivaroxaban | 141 | 19 |
| Meloxicam | Meloxicam | 133 | 35 |
| Clonidine Hcl | Clonidine Hcl | 128 | 37 |
| Ozempic | Semaglutide | 127 | 33 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 124 | 40 |
| Januvia | Sitagliptin Phosphate | 115 | 18 |
| Simvastatin | Simvastatin | 112 | 30 |
| Lorazepam | Lorazepam | 108 | 27 |
| Lactulose | Lactulose | 107 | 39 |
| Metformin Hcl Er | Metformin Hcl | 105 | 33 |
| Pioglitazone Hcl | Pioglitazone Hcl | 103 | 27 |
| Levetiracetam | Levetiracetam | 102 | 25 |
| Sucralfate | Sucralfate | 102 | 22 |
| Albuterol Sulfate | Albuterol Sulfate | 101 | 55 |
| Citalopram Hbr | Citalopram Hydrobromide | 99 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 96 | 27 |
| Spironolactone | Spironolactone | 92 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 88 | 20 |
| Labetalol Hcl | Labetalol Hcl | 87 | 18 |
| Misoprostol | Misoprostol | 85 | suppressed |
| Enulose | Lactulose | 84 | 20 |
| Irbesartan | Irbesartan | 84 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 82 | 22 |
| Fenofibrate | Fenofibrate Nanocrystallized | 80 | 21 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 77 | 18 |
| Ceftriaxone | Ceftriaxone Sodium | 77 | 40 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 75 | 23 |
| Temazepam | Temazepam | 75 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 74 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 74 | 14 |
| Alendronate Sodium | Alendronate Sodium | 73 | 23 |
| Midodrine Hcl | Midodrine Hcl | 72 | 17 |
| Mounjaro | Tirzepatide | 71 | 17 |
| Pregabalin | Pregabalin | 70 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 67 | 21 |
| Amiodarone Hcl | Amiodarone Hcl | 66 | 24 |
| Calcium Acetate | Calcium Acetate | 66 | 11 |
| Ibuprofen | Ibuprofen | 62 | 33 |
| Dapagliflozin | Dapagliflozin Propanediol | 61 | 28 |
| Meclizine Hcl | Meclizine Hcl | 61 | 25 |
| Raloxifene Hcl | Raloxifene Hcl | 61 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 60 | 21 |
| Allopurinol | Allopurinol | 59 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 59 | 16 |
| Glimepiride | Glimepiride | 58 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 57 | 32 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 55 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | 14 |
| Azithromycin | Azithromycin | 53 | 44 |
| Ezetimibe | Ezetimibe | 53 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 53 | 20 |
| Naproxen | Naproxen | 52 | 31 |
| Trulicity | Dulaglutide | 52 | 13 |
| Valsartan | Valsartan | 51 | 15 |
| Verapamil Er | Verapamil Hcl | 51 | suppressed |
| Digoxin | Digoxin | 50 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 49 | 33 |
| Tradjenta | Linagliptin | 49 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 47 | 16 |
| Ketoconazole | Ketoconazole | 47 | 17 |
| Linzess | Linaclotide | 46 | 15 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 45 | 23 |
| Verapamil Er Pm | Verapamil Hcl | 45 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 17 |
| Latanoprost | Latanoprost | 43 | 13 |
| Megestrol Acetate | Megestrol Acetate | 43 | 18 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 42 | 25 |
| Myrbetriq | Mirabegron | 42 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 42 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 41 | suppressed |
| Cilostazol | Cilostazol | 40 | suppressed |
| Ramipril | Ramipril | 40 | 11 |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 40 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 40 | suppressed |
| Dutasteride | Dutasteride | 39 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 39 | 17 |
| Olanzapine | Olanzapine | 39 | 11 |
| Santyl | Collagenase Clostridium Hist. | 38 | 22 |
| Cephalexin | Cephalexin | 36 | 25 |
| Entresto | Sacubitril/Valsartan | 36 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 36 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 36 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 36 | suppressed |
| Ursodiol | Ursodiol | 36 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 35 | 11 |
| Fenofibric Acid | Fenofibric Acid (Choline) | 35 | suppressed |
| Prednisone | Prednisone | 35 | 17 |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Lamotrigine | Lamotrigine | 34 | suppressed |
| Creon | Lipase/Protease/Amylase | 33 | suppressed |
| Fluocinonide | Fluocinonide | 33 | 16 |
| Rybelsus | Semaglutide | 33 | suppressed |
| Baclofen | Baclofen | 32 | 13 |
| Isentress | Raltegravir Potassium | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 31 | suppressed |
| Scopolamine | Scopolamine | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 15 |
| Humalog Kwikpen U-100 | Insulin Lispro | 30 | 18 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 29 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 21 |
| Atenolol | Atenolol | 28 | suppressed |
| Entacapone | Entacapone | 28 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 20 |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 17 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 27 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 27 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 27 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 26 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 20 |
| Diltiazem 24hr Er | Diltiazem Hcl | 26 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 26 | 21 |
| Ertapenem | Ertapenem Sodium | 25 | suppressed |
| Xtampza Er | Oxycodone Myristate | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Vascepa | Icosapent Ethyl | 24 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 23 | suppressed |
| Kerendia | Finerenone | 23 | suppressed |
| Paricalcitol | Paricalcitol | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Procrit | Epoetin Alfa | 23 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Triazolam | Triazolam | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Levemir Flexpen | Insulin Detemir | 20 | suppressed |
| Nexletol | Bempedoic Acid | 20 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | 16 |
| Incontrol Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 19 | 11 |
| Metolazone | Metolazone | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Propafenone Hcl | Propafenone Hcl | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 12 |
| Anastrozole | Anastrozole | 18 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 18 | suppressed |
| Clonidine | Clonidine | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Rexulti | Brexpiprazole | 18 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Dexamethasone | Dexamethasone | 17 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 17 | suppressed |
| Nystatin | Nystatin | 17 | 11 |
| Ondansetron Odt | Ondansetron | 17 | 12 |
| Topiramate | Topiramate | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | 13 |
| Glipizide | Glipizide | 15 | suppressed |
| Nyamyc | Nystatin | 15 | suppressed |
| Permethrin | Permethrin | 15 | 12 |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Lumigan | Bimatoprost | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Budesonide | Budesonide | 13 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 13 | suppressed |
| Humalog | Insulin Lispro | 13 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Dovato | Dolutegravir Sodium/Lamivudine | 12 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Leflunomide | Leflunomide | 12 | suppressed |
| Levofloxacin-D5w | Levofloxacin In Dextrose 5 % | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Sulfasalazine | Sulfasalazine | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Darunavir | Darunavir | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 11 | suppressed |
| Hydroxyurea | Hydroxyurea | 11 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Meropenem | Meropenem | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $320.21 · 10 records | ViiV Healthcare Company | BEXSERO, CABENUVA, CAPVAXIVE, GARDASIL 9, JARDIANCE, MOUNJARO, PURIFIED CORTROPHIN GEL, REXULTI, SHINGRIX, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error